Wegovy leads to ‘substantial’ BMI decrease for children

NATIONAL HARBOR, Md. — Once-weekly injectable semaglutide reduced BMI for children with obesity as young as age 6 years, according to data from the phase 3 STEP Young trial presented at ObesityWeek.
As Healio previously reported, semaglutide (Wegovy, Novo Nordisk) was approved by the FDA for adolescents aged 12 to 17 years in December 2022. Martin Wabitsch, MD, PhD, professor of pediatrics at Ulm University Medical Center in Germany, said there are no GLP-1 receptor agonists approved in the U.S. for children younger than age 12 years, and early treatment of obesity could help children avoid

First MTPJ arthrodesis may decrease pain for symptomatic OA

First metatarsophalangeal joint arthrodesis may improve pain and function for patients who are 40 years or older with persistent osteoarthritis symptoms, according to results.
“First MTP [joint] arthrodesis resulted in clinically significant improvement in walking-related pain at 12 months compared with watchful waiting,” Mikko Miettinen, MD, an orthopedic surgeon and researcher in the department of orthopedics and traumatology at University of Helsinki and Helsinki University Hospital in Helsinki, Finland, and colleagues wrote. “These findings support arthrodesis as the

Retinal age shows strength, limitations as disease biomarker

VIENNA — Retinal age is a promising, noninvasive biomarker of biological aging and systemic health, but there are limitations to the reliability of current models, and further studies are needed.
At the Euretina congress, Siegfried Wagner, MD, PhD, presented research from Moorfields Eye Hospital and University College London on oculomics and retinal age. The goal was to establish whether the retinal age gap could be a clinically significant biomarker of systemic diseases.
“The concept of retinal age gap was first introduced by Lisa Zhuoting Zhu and Mingguang He from the University of

CMS final rule reduces cuts, preserves access to orthopedic care

The American Academy of Orthopaedic Surgeons is “cautious” after cuts proposed by CMS’ 2027 Medicare Physician Fee Schedule for total joint arthroplasty and shoulder hemiarthroplasty were reduced nearly 50%, according to a press release.
The AAOS also calls for further reform in the release.
"When the Notice of Proposed Rulemaking dropped back in July, our position from the start has been to pause the cuts,” Wilford K. Gibson, MD, FAAOS, president of the AAOS, told Healio. “These are cumulative cuts, which the people who do hip and knee replacements feel the most.”

Amblyopia controlled for months after stopping Luminopia

ANAHEIM, Calif. — Children with amblyopia treated with Luminopia had stable visual acuity and a low rate of recurrence up to a year after stopping treatment, according to data presented at Academy 2026.
For a real-world study of treatment outcomes with Luminopia, Alexandra Williamson OD, FAAO, FLCSA, pediatric optometrist at the Cleveland Clinic Cole Eye Institute, and colleagues analyzed data from the company’s PUPiL registry. They included data on 84 children who started Luminopia at an average age of 7.2 years and used it for an average of 8.3 months.
{{VIDEO}}
After undergoing an average of

As vitamin K refusals rise, so does vitamin K deficiency bleeding

The proportion of infants who do not receive vitamin K after birth has increased alongside vitamin K deficiency bleeding, according to two studies.
The AAP has recommended intramuscular vitamin K for all newborns since 1961 to reduce the risk for vitamin K deficient bleeding — a rare but serious condition that can occur in infants early in life.
Recent studies have shown an uptick in parents refusing vitamin K prophylaxis for their newborns, especially for female infants.
“Not receiving vitamin K can have devastating consequences,” Kristan Scott, MD, MSHP, a neonatologist at Children’s

Cleveland Clinic planning to open new neurological building

A new 1 million-square foot neurology building at the Cleveland Clinic will be designed for researching and treating conditions that affect the brain, nervous system and spine, according to a press release.
Beyond putting all neurological care elements under one roof, the building will allow physicians to rethink neurological care entirely, said Robert Bermel, MD, neurologist and director of the Mellen Center at Cleveland Clinic.
“The goal is not just more capacity, but a much more integrated model of neurological care,” Bermel told Healio.
The facility will be located on the Cleveland Clinic’s

More data support effectiveness of RSV mRNA vaccine in older adults

Moderna’s messenger RNA-1345 vaccine was associated with a lower risk for RSV infections and related healthcare use among veterans, according to a recently published study.
“Clinicians now have several vaccine options to offer patients in this age group who may be at increased risk for severe RSV,” Kristina L. Bajema, MD, an associate professor of medicine at Oregon Health and Science University’s division of infectious diseases, told Healio. “Vaccination is the most important tool for preventing serious RSV illness in at-risk groups.”
According to Bajema and colleagues, the Veterans Health

FDA rejects ivonescimab application for NSCLC types

The FDA issued a complete response letter to Summit Therapeutics stating it cannot approve the company’s biologic license application for ivonescimab as treatment for EGFR-mutated, locally advanced or metastatic non-small cell lung cancer.
The company had submitted the application for ivonescimab (SMT112, Summit Therapeutics) — an investigational bispecific antibody that targets PD-1 and VEGF — in combination with platinum-containing chemotherapy for patients who received prior EGFR tyrosine kinase inhibitor (TKI) therapy.
The FDA wrote that it is unable to approve the biologics license

Tirzepatide confers ‘robust’ weight loss for teens with obesity

NATIONAL HARBOR, Md. — Once-weekly tirzepatide reduced BMI more than placebo and also conferred a range of cardiometabolic benefits among adolescents with overweight or obesity, according to data from the SURMOUNT-ADOLESCENTS trial.
As Healio previously reported, the FDA approved once-weekly subcutaneous semaglutide (Wegovy, Novo Nordisk) in 2022 as the first incretin-based medication to treat adolescents with obesity. New data from SURMOUNT-ADOLESCENTS revealed that the GLP-1/GIP dual receptor agonist tirzepatide (Zepbound, Eli Lilly) also induced large reductions in body weight and